DK0804166T3 - Formulering med kontrolleret frigivelse (Albuterol) - Google Patents
Formulering med kontrolleret frigivelse (Albuterol)Info
- Publication number
- DK0804166T3 DK0804166T3 DK96940352.6T DK96940352T DK0804166T3 DK 0804166 T3 DK0804166 T3 DK 0804166T3 DK 96940352 T DK96940352 T DK 96940352T DK 0804166 T3 DK0804166 T3 DK 0804166T3
- Authority
- DK
- Denmark
- Prior art keywords
- albuterol
- controlled
- release formulation
- sustained release
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/553,008 US5662933A (en) | 1993-09-09 | 1995-11-03 | Controlled release formulation (albuterol) |
PCT/US1996/017991 WO1997016172A1 (en) | 1995-11-03 | 1996-11-04 | Controlled release formulation (albuterol) |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0804166T3 true DK0804166T3 (da) | 2011-08-15 |
Family
ID=24207743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96940352.6T DK0804166T3 (da) | 1995-11-03 | 1996-11-04 | Formulering med kontrolleret frigivelse (Albuterol) |
Country Status (12)
Country | Link |
---|---|
US (2) | US5662933A (da) |
EP (2) | EP2286796A3 (da) |
JP (1) | JP3250737B2 (da) |
KR (2) | KR100264024B1 (da) |
AT (1) | ATE507820T1 (da) |
AU (1) | AU7725396A (da) |
CA (1) | CA2208230C (da) |
DE (1) | DE69638364D1 (da) |
DK (1) | DK0804166T3 (da) |
ES (1) | ES2366278T3 (da) |
MX (1) | MX9704910A (da) |
WO (1) | WO1997016172A1 (da) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US6726930B1 (en) * | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5662933A (en) * | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
FR2729857B1 (fr) * | 1995-01-27 | 1997-04-04 | Rhone Poulenc Chimie | Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire |
CZ298690B6 (cs) * | 1995-12-27 | 2007-12-27 | Tibotec Pharmaceuticals Ltd. | Bioadhezivní farmaceutická kompozice, dávková forma a suchý zpusob prípravy tablet |
AU2068797A (en) * | 1996-01-29 | 1997-08-20 | Edward Mendell Co. Inc. | Sustained release excipient |
AU695734B2 (en) | 1996-07-08 | 1998-08-20 | Penwest Pharmaceuticals Co. | Sustained release matrix for high-dose insoluble drugs |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
US6210710B1 (en) * | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
US6929936B1 (en) * | 1997-07-18 | 2005-08-16 | Danisco A/S | Composition comprising an enzyme having galactose oxidase activity and use thereof |
IN186245B (da) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
DE59804823D1 (de) * | 1997-09-25 | 2002-08-22 | Bayer Ag | Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
WO1999042460A1 (en) * | 1998-02-20 | 1999-08-26 | Fine Chemicals Corporation (Proprietary) Limited | Process for the production of optically enriched (r)- or (s)-albuterol |
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
DE69940557D1 (de) | 1998-12-11 | 2009-04-23 | Nostrum Pharmaceuticals Inc | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung |
CA2372994C (en) * | 1999-06-04 | 2010-03-23 | Alza Corporation | Implantable gel compositions and method of manufacture |
US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
CA2352211C (en) * | 1999-09-30 | 2009-03-24 | Edward Mendell Co., Inc. | Sustained release matrix systems for highly soluble drugs |
US20060153914A1 (en) * | 1999-12-10 | 2006-07-13 | Biovail Laboratories International S.R.L. | Chronotherapeutic diltiazem formulations and the administration thereof |
US7108866B1 (en) | 1999-12-10 | 2006-09-19 | Biovall Laboratories International Srl | Chronotherapeutic diltiazem formulations and the administration thereof |
US7892586B2 (en) | 2001-02-22 | 2011-02-22 | Suzanne Jaffe Stillman | Water containing soluble fiber |
US8178150B2 (en) | 2000-02-22 | 2012-05-15 | Suzanne Jaffe Stillman | Water containing soluble fiber |
US6955821B2 (en) | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
US7838032B2 (en) * | 2000-04-28 | 2010-11-23 | Reckitt Benckiser Inc. | Sustained release of guaifenesin |
US6372252B1 (en) | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
US7985420B2 (en) * | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US8012504B2 (en) * | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US7056531B1 (en) | 2000-05-04 | 2006-06-06 | Nature's Way Products, Inc. | Sustained release compositions for orally administered substances and methods |
AU2001275043A1 (en) | 2000-05-31 | 2001-12-11 | Drugtech Corporation | Mineral supplement |
CA2440641A1 (en) * | 2001-03-13 | 2002-09-19 | Anand R. Baichwal | Chronotherapeutic dosage forms containing glucocorticosteroid |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US7276250B2 (en) * | 2001-07-06 | 2007-10-02 | Penwest Pharmaceuticals Company | Sustained release formulations of oxymorphone |
CA2452872A1 (en) | 2001-07-06 | 2003-01-16 | Endo Pharmaceuticals, Inc. | Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
CA2459976A1 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
WO2003086353A1 (en) * | 2002-04-05 | 2003-10-23 | Penwest Pharmaceuticals Co. | Sustained release metoprolol formulations |
US7125563B2 (en) * | 2002-04-12 | 2006-10-24 | Dava Pharmaceuticals, Inc. | Sustained release pharmaceutical preparations and methods for producing the same |
AU2003261298A1 (en) * | 2002-08-02 | 2004-02-23 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
WO2005007074A2 (en) * | 2003-07-21 | 2005-01-27 | Bio-Dar Ltd. | Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention |
NZ545921A (en) * | 2003-09-19 | 2009-09-25 | Penwest Pharmaceuticals Co | Delayed released dosage forms |
US20050118267A1 (en) * | 2003-09-19 | 2005-06-02 | Penwest Pharmaceuticals Co. | Chronotherapeutic dosage forms |
US8481565B2 (en) | 2004-12-27 | 2013-07-09 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
US20060159753A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
US20060228413A1 (en) * | 2005-02-28 | 2006-10-12 | Penwest Pharmaceuticals Co. | Controlled release venlafaxine formulations |
JP5406529B2 (ja) * | 2005-10-26 | 2014-02-05 | バナー ファーマキャプス, インコーポレイテッド | カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム |
KR100753480B1 (ko) * | 2006-01-27 | 2007-08-31 | 씨제이 주식회사 | 잘토프로펜 함유 서방성 정제 및 그 제조방법 |
US20070281016A1 (en) * | 2006-06-06 | 2007-12-06 | Endo Pharmaceuticals Inc., A Delaware Corporation | Sustained release oxycodone composition with acrylic polymer and surfactant |
EP2096923B1 (en) | 2006-11-27 | 2014-01-22 | H. Lundbeck A/S | Heteroaryl amide derivatives |
EP2544667B1 (en) * | 2010-03-09 | 2018-11-14 | Alkermes Pharma Ireland Limited | Alcohol resistant enteric pharmaceutical compositions |
US9901540B2 (en) | 2010-05-10 | 2018-02-27 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
EA201291211A1 (ru) | 2010-05-10 | 2013-05-30 | Эро-Селтик С.А. | Фармацевтические композиции, содержащие гидроморфон и налоксон |
CN103002882B (zh) * | 2010-05-10 | 2016-03-02 | 欧洲凯尔特公司 | 不含活性剂之颗粒及包含其之片剂的制备 |
US10137093B2 (en) | 2011-08-16 | 2018-11-27 | Cardiora Pty Ltd. | Milrinone controlled-release formulation |
DE102012014848A1 (de) * | 2012-07-27 | 2012-10-31 | Heilerde-Gesellschaft Luvos Just GmbH & Co. KG | Heilerde-Zubereitung |
KR102194174B1 (ko) | 2013-11-13 | 2020-12-23 | 유로-셀티큐 에스.에이. | 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손 |
CN107530337B (zh) | 2014-12-22 | 2021-07-09 | 贝克心脏与糖尿病研究所 | 治疗方法 |
CA3001337C (en) | 2015-10-09 | 2023-12-12 | Reckitt Benckiser Llc | Pharmaceutical formulation |
WO2018143423A1 (ja) * | 2017-02-03 | 2018-08-09 | 株式会社東洋新薬 | 固形製剤 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1579818A (en) * | 1977-06-07 | 1980-11-26 | Yamanouchi Pharma Co Ltd | Nifedipine-containing solid preparation composition |
CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
US4309405A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
JPS5846019A (ja) * | 1981-09-14 | 1983-03-17 | Kanebo Ltd | 持続性ニフエジピン製剤 |
DE3318649A1 (de) * | 1983-05-21 | 1984-11-22 | Bayer Ag, 5090 Leverkusen | Zweiphasenformulierung |
US4851229A (en) * | 1983-12-01 | 1989-07-25 | Alza Corporation | Composition comprising a therapeutic agent and a modulating agent |
US4610870A (en) * | 1984-10-05 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
DE3586713T2 (de) * | 1984-11-15 | 1993-05-13 | Hercon Lab | Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen. |
GB8514665D0 (en) * | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
GB8601204D0 (en) | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
IE63321B1 (en) * | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
DE3636123A1 (de) * | 1986-10-23 | 1988-05-05 | Rentschler Arzneimittel | Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten |
ATE68704T1 (de) * | 1986-12-18 | 1991-11-15 | Bauer Kurt Heinz | Gegenueber lichteinfluss stabilisiertes nifedipin- konzentrat und verfahren zu seiner herstellung. |
IE59540B1 (en) * | 1987-01-09 | 1994-03-09 | Elan Corp | Sustained release capsule or tablet formulation |
GB8705083D0 (en) * | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
US4808413A (en) * | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
DE3720757A1 (de) * | 1987-06-24 | 1989-01-05 | Bayer Ag | Dhp-manteltablette |
FR2618073B1 (fr) * | 1987-07-16 | 1990-09-07 | Pf Medicament | Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation |
US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4994276A (en) * | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
GB8722306D0 (en) * | 1987-09-22 | 1987-10-28 | Aps Research Ltd | Sustained-release formulation |
SE8703881D0 (sv) * | 1987-10-08 | 1987-10-08 | Haessle Ab | New pharmaceutical preparation |
GB8723896D0 (en) * | 1987-10-12 | 1987-11-18 | Aps Research Ltd | Controlled-release formulation |
EP0357793B1 (en) * | 1988-03-09 | 1994-05-25 | Snow Brand Milk Products Co., Ltd. | Suspended-release preparation prepared by using alginates |
US5019397A (en) * | 1988-04-21 | 1991-05-28 | Alza Corporation | Aqueous emulsion for pharmaceutical dosage form |
US5135757A (en) * | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
US5128143A (en) * | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
GB8903328D0 (en) * | 1989-02-14 | 1989-04-05 | Ethical Pharma Ltd | Nifedipine-containing pharmaceutical compositions and process for the preparation thereof |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
GB9022788D0 (en) * | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
US5215758A (en) * | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
US5273760A (en) * | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5264459A (en) * | 1992-07-13 | 1993-11-23 | Arch Development Corporation | Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases |
US5324351A (en) * | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
US5662933A (en) * | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
-
1995
- 1995-11-03 US US08/553,008 patent/US5662933A/en not_active Expired - Lifetime
-
1996
- 1996-11-04 ES ES96940352T patent/ES2366278T3/es not_active Expired - Lifetime
- 1996-11-04 KR KR1019970704570A patent/KR100264024B1/ko not_active IP Right Cessation
- 1996-11-04 JP JP51763797A patent/JP3250737B2/ja not_active Expired - Fee Related
- 1996-11-04 DE DE69638364T patent/DE69638364D1/de not_active Expired - Lifetime
- 1996-11-04 WO PCT/US1996/017991 patent/WO1997016172A1/en active IP Right Grant
- 1996-11-04 EP EP10178632A patent/EP2286796A3/en not_active Withdrawn
- 1996-11-04 DK DK96940352.6T patent/DK0804166T3/da active
- 1996-11-04 AU AU77253/96A patent/AU7725396A/en not_active Abandoned
- 1996-11-04 EP EP96940352A patent/EP0804166B1/en not_active Expired - Lifetime
- 1996-11-04 AT AT96940352T patent/ATE507820T1/de active
- 1996-11-04 CA CA002208230A patent/CA2208230C/en not_active Expired - Fee Related
-
1997
- 1997-06-27 MX MX9704910A patent/MX9704910A/es active IP Right Grant
- 1997-07-01 US US08/886,496 patent/US5958456A/en not_active Expired - Lifetime
-
2000
- 2000-01-07 KR KR1020000000749A patent/KR20000018064A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20000018064A (ko) | 2000-04-06 |
ATE507820T1 (de) | 2011-05-15 |
AU7725396A (en) | 1997-05-22 |
EP2286796A2 (en) | 2011-02-23 |
EP0804166A1 (en) | 1997-11-05 |
DE69638364D1 (de) | 2011-06-16 |
EP0804166A4 (en) | 2004-12-29 |
CA2208230C (en) | 2001-12-25 |
CA2208230A1 (en) | 1997-05-09 |
JP3250737B2 (ja) | 2002-01-28 |
MX9704910A (es) | 1998-06-30 |
US5958456A (en) | 1999-09-28 |
ES2366278T3 (es) | 2011-10-18 |
WO1997016172A1 (en) | 1997-05-09 |
JPH10507210A (ja) | 1998-07-14 |
EP0804166B1 (en) | 2011-05-04 |
US5662933A (en) | 1997-09-02 |
EP2286796A3 (en) | 2012-02-22 |
KR100264024B1 (ko) | 2000-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0804166T3 (da) | Formulering med kontrolleret frigivelse (Albuterol) | |
FI961996A0 (fi) | Pitkitetysti vapauttavat valmisteet metoprololin 24 tunnin pituiseksi vapauttamiseksi | |
DK0700284T3 (da) | Oxybutyninformuleringer med kontrolleret frigivelse | |
CA2164619A1 (en) | Once-a-day metoprolol oral dosage form | |
AU671384B2 (en) | Sustained release drug formulation containing a tramadol salt | |
AU651894B2 (en) | Matrix tablet permitting the sustained release of indapamide after oral administration | |
NZ264487A (en) | Tetracycline based prodrug conjugate, pharmaceutical compositions thereof | |
DE60042972D1 (de) | Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung |